THE US Food and Drug Administration has approved Ogivri (trastuszumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer whose tumours overexpress the HER2 gene.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 17
